LOW FEASIBILITY OF SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH DIABETES MELLITUS IN ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Kogure, Yoshihito [1 ]
Hori, Kazumi [1 ]
Funahashi, Yoriko [1 ]
Oka, Saori [1 ]
Tsuboi, Rie [1 ]
Adachi, Takashi [1 ]
Ryuge, Misaki [1 ]
Murata, Naohiko [1 ]
Kitagawa, Chiyoe [1 ]
Oki, Masahide [1 ]
Saka, Hideo [1 ]
机构：
[1] Nagoya Med Ctr, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; Chemotherapy; diabetes mellitus;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1182 / S1183
页数：2
相关论文
共 50 条
  • [21] Non-small cell lung cancer: second-line and beyond
    Stahel, R. A.
    ANNALS OF ONCOLOGY, 2006, 17 : X97 - X100
  • [22] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [23] The Efficacy and Safety of PlatinumNinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
    Song, Ik-Chan
    Lee, Hyo-Jin
    Yang, Young-Jun
    Choi, Yoon-Seok
    Ryu, Hye-Won
    Lee, Myung-Won
    Moon, Ji Young
    Jo, Deog-Yeon
    Kim, Samyong
    Yun, Hwan-Jung
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 638 - 644
  • [24] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [25] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [26] Second-line treatment for advanced non-small cell lung cancer:: A systematic review
    Barlési, F
    Jacot, W
    Astoul, P
    Pujol, JL
    LUNG CANCER, 2006, 51 (02) : 159 - 172
  • [27] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [28] Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small cell lung cancer (NSCLC)
    Teramukai, S.
    Nishimura, T.
    Nakagawa, M.
    Kawahara, M.
    Kubota, K.
    Furuse, K.
    Fukushima, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
    Reckamp, Karen L.
    CANCER LETTERS, 2012, 321 (02) : 101 - 109
  • [30] Oral second-line chemotherapy for advanced non-small-cell lung cancer: The bottom line
    Gandara, David R.
    Davies, Angela M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2700 - 2701
12345